

## Certificate of Analysis

[www.tocris.com](http://www.tocris.com)

**Product Name:** UFP 803  
**CAS Number:** 879497-82-2

**Catalog No.:** 2529      **Batch No.:** 1

### 1. PHYSICAL AND CHEMICAL PROPERTIES

**Batch Molecular Formula:** C<sub>50</sub>H<sub>64</sub>N<sub>10</sub>O<sub>12</sub>S<sub>2</sub>  
**Batch Molecular Weight:** 1061.24  
**Physical Appearance:** White lyophilised solid  
**Net Peptide Content:** 85%  
**Counter Ion:** Trifluoroacetate  
**Solubility:** Soluble in water  
**Storage:** Desiccate at -20°C  
**Peptide Sequence:** Asp-Pen-Phe-D-Trp-Dab-Tyr-Cys-Val

### 2. ANALYTICAL DATA

**HPLC:** Shows >97.1% purity  
**Mass Spectrum:** Consistent with structure

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**bio-techne.com**  
info@bio-techne.com  
techsupport@bio-techne.com

**North America**  
Tel: (800) 343 7475

**China**  
info.cn@bio-techne.com  
Tel: +86 (21) 52380373

**Europe Middle East Africa**  
Tel: +44 (0)1235 529449

**Rest of World**  
[www.tocris.com/distributors](http://www.tocris.com/distributors)  
Tel: +1 612 379 2956

**Product Name:** UFP 803

**Catalog No.:** 2529

**Batch No.:** 1

CAS Number: 879497-82-2

**Description:**

Urotensin-II (UT) receptor ligand; behaves as a silent antagonist in most in vitro assays and in vivo, but does retain small residual agonist activity under certain conditions in some assays. Competitively antagonizes U-II induced contractions in the rat aorta (pIC<sub>50</sub> = 7.46) and prevents plasma extravasation elicited by U-II in mice in vivo.

**Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>50</sub>H<sub>64</sub>N<sub>10</sub>O<sub>12</sub>S<sub>2</sub>

Batch Molecular Weight: 1061.24

Physical Appearance: White lyophilised solid

**Peptide Sequence:**

Asp-Pen-Phe-D-Trp-Dab-Tyr-Cys-Val

**Storage:** Desiccate at -20°C

**Solubility & Usage Info:**

Soluble in water

This product is supplied as a lyophilized solid and may be very hard to visualize. Solutions should be made by adding solvent directly to the vial. The vial should then be vortexed vigorously to ensure the product has completely dissolved.

**Net Peptide Content:** 85% (Remaining weight made up of counterions and residual water).

**Counter Ion:** Trifluoroacetate

**Stability and Solubility Advice:**

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Peptides in solution are much less stable than in lyophilized form. This is especially true for peptides whose sequences contain amino acids such as Cys, Met, Trp, Asn, Gln, and N-terminal Glu.

Therefore we recommend storing peptides in solution for as short a time as possible. Avoid repeated freeze thaw cycles by dividing the peptide solution into aliquots and storing the aliquots at -20°C. Any portion of an aliquot unused after thawing should be discarded.

Peptides stored in solution can occasionally be susceptible to bacterial degradation. We recommend using sterile solutions or passing the peptide solution through a 0.2 µm filter to remove potential bacterial contamination whenever possible.

**References:**

**Camarda et al** (2006) *In vitro* and *in vivo* pharmacological characterization of the novel UT receptor ligand [Pen<sup>5</sup>,DTrp<sup>7</sup>,Dab<sup>8</sup>]urotensin II (4-11) (UFP-803). *Br.J.Pharmacol.* **147** 92. PMID: 16273120.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**bio-techne.com**

info@bio-techne.com

techsupport@bio-techne.com

**North America**

Tel: (800) 343 7475

**China**

info.cn@bio-techne.com

Tel: +86 (21) 52380373

**Europe Middle East Africa**

Tel: +44 (0)1235 529449

**Rest of World**

www.tocris.com/distributors

Tel:+1 612 379 2956